MEDVi vs Hers vs PlexusDx (2026)

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

If you're cross-shopping MEDVi and Hers for cash-pay GLP-1 weight loss, the headline numbers in each provider's ad copy do not reflect what you actually pay over twelve months. MEDVi advertises $179 for month one then $299/month with the compounded medication included; Hers now layers a required Weight Loss Membership on top of separate medication pricing — Wegovy® pill from $149/mo, Wegovy® pen and Ozempic® from $199/mo, generic liraglutide from $299/mo — with the membership billed independently. Older Hers materials still reference compounded semaglutide multi-month plans starting near $199/mo. The two pricing pages look broadly comparable in screenshots; in your bank account at month twelve, they are not. This article walks the actual cost math, the medication-source difference (compounded vs FDA-approved branded), the safety considerations on each side, and where PlexusDx Semaglutide Injection, Tirzepatide Injection, and Microdose GLP-1 Protocol sit relative to both — because the choice between MEDVi, Hers, and PlexusDx isn't really about which platform has the slickest app. It's about medication source, total annualized cost, tirzepatide availability, and whether genetics inform your dose before week one.

MEDVi vs Hers vs PlexusDx — quick decision frame

Three pricing models cover the cash-pay GLP-1 market in 2026. MEDVi is an all-inclusive compounded-medication platform: $179 first month, $299/month ongoing, billed month-to-month, covering the clinician visit, the compounded semaglutide or tirzepatide vials, supplies, and shipping in one charge. Hers is a membership-plus-medication model: a required Weight Loss Membership runs alongside separate medication pricing — current Hers product pages list Wegovy® pill from $149/mo, Wegovy® pen and Ozempic® from $199/mo, and generic liraglutide from $299/mo, with a polished iOS/Android app and a dedicated Care Team. Some Hers materials still reference compounded semaglutide tied to 2-, 4-, and 6-month commitments. PlexusDx Weight Management Protocols use compounded semaglutide and tirzepatide from licensed U.S. compounding pharmacies — Semaglutide Injection at $149/mo, Tirzepatide Injection at $249/mo, Microdose GLP-1 Protocol at $129/mo flat, and GLP-Squared dual-compound at $249/mo — paired with the optional Precision Peptide Genetic Test ($298 standalone or $99 as an add-on after your first month) so dosing decisions are anchored to the patient's GLP1R, GIPR rs1800437, FTO, MC4R, and TCF7L2 variants rather than starting from population averages. All three platforms are cash-pay; PlexusDx adds no membership fee.

The real annual cost: MEDVi vs Hers vs PlexusDx

For a cash-pay patient with no insurance coverage for weight-loss drugs, MEDVi's all-inclusive pricing produces a total of roughly $3,468/year on the standard plan ($179 month one + $299 × 11). Hers's branded-medication path runs higher: Wegovy® pill at $149/mo plus the required Weight Loss Membership pushes the annual total above the headline price; Wegovy® pen and Ozempic® at $199/mo plus membership lands meaningfully above MEDVi; generic liraglutide at $299/mo plus membership is in the same neighborhood as MEDVi or slightly above. PlexusDx Weight Management Protocols range from $1,548/year on the Microdose GLP-1 Protocol ($129/mo flat) to $2,148–$2,748/year on Semaglutide Injection ($149/mo), $2,748–$3,708/year on Tirzepatide Injection ($249/mo), or $2,148–$3,900/year on GLP-Squared ($249/mo). Add $99 for the Precision Peptide Genetic Test as an add-on after month one and the genetic-baseline-included totals stay below MEDVi on the lower-cost protocols. If you carry insurance that reliably covers Wegovy or Zepbound at a low copay, Hers's branded route plus your benefit may still win on out-of-pocket. If your insurance does not cover GLP-1s for weight loss — the case for most commercial plans as of April 2026 — PlexusDx's protocol pricing is meaningfully below MEDVi at the entry tier and competitive at the higher tiers.

Compounded vs FDA-approved branded — what each platform actually dispenses

This is the substantive medication difference and it's worth understanding before signing up for any of the three. MEDVi's core all-inclusive plans dispense compounded semaglutide and tirzepatide — formulations prepared by a licensed compounding pharmacy under U.S. compounding regulations. Compounded semaglutide and tirzepatide are not FDA-approved finished drug products; they are pharmacy-prepared versions of the same active ingredients found in Wegovy, Ozempic, Mounjaro, and Zepbound. Hers's primary current weight-loss path foregrounds FDA-approved branded GLP-1 medications — Wegovy® pill (oral semaglutide), Wegovy® pen (injectable semaglutide), Ozempic®, plus brand-name listings for Mounjaro® and Zepbound®. Hers also lists generic liraglutide and previously offered a $49 compounded semaglutide product that was withdrawn from the platform in February 2026. PlexusDx Weight Management Protocols use compounded semaglutide and tirzepatide like MEDVi, but offer four delivery formats — weekly injection, daily oral tablet, microdose troche/capsule/lozenge/sublingual, and dual-compound stacks — at protocol-specific dose ranges, paired with an optional genetic baseline. The compounded vs branded choice is not about effectiveness of the active ingredient — it's about FDA approval status of the finished product, supply consistency, and which regulatory framework governs your medication. For a tirzepatide-curious patient, MEDVi and PlexusDx both offer compounded tirzepatide; Hers does not currently offer a compounded tirzepatide product on its weight-loss platform.

Safety, side effects, and clinical oversight

All three programs prescribe medications in the GLP-1 receptor agonist class (and tirzepatide, a GIP/GLP-1 dual agonist). The FDA-labeled side-effect profile is well-characterized: nausea, vomiting, diarrhea, constipation, abdominal pain, and headache are common; pancreatitis, gallbladder disease, and acute kidney injury are less common but documented; the boxed warning for thyroid C-cell tumors applies to both semaglutide and tirzepatide based on rodent studies and applies regardless of whether the medication is the FDA-approved branded product or a compounded version of the same active ingredient. The clinical-oversight question differs by platform. Hers routes prescriptions through licensed providers and partner pharmacies; for branded products, the FDA-approved label and post-market surveillance apply directly. MEDVi routes through a licensed clinician and a compounding pharmacy. PlexusDx uses licensed U.S. compounding pharmacies and a clinical team that reviews the patient's genetic test before titration when the test is included. Both MEDVi (February 20, 2026) and Hers (September 9, 2025) have received FDA warning letters regarding marketing language — in both cases marketing issues, not safety recalls — which is worth weighing in your due diligence regardless of which provider you choose.

Tirzepatide availability and dose flexibility

Tirzepatide (a dual GIP/GLP-1 agonist) is the second-line option many patients want as a backup if compounded semaglutide stalls plateau-side. MEDVi offers compounded tirzepatide injectable starting at $349/mo and tablets starting at $279/mo, providing a switch path inside the same platform. Hers currently does not offer compounded tirzepatide; the brand-name Mounjaro® and Zepbound® are listed on Hers's broader weight-loss pages but at branded retail tiers rather than compounded pricing. PlexusDx offers Tirzepatide Injection at $249/mo across six dose levels (2.5mg to 15mg weekly), Tirzepatide Oral at $279/mo across seven dose levels (5mg to 25mg daily), and GLP-Squared at $249/mo for patients whose clinician decides a stacked semaglutide + tirzepatide approach fits the response pattern better than either compound alone. For a patient who values keeping tirzepatide on the table as a switch option, PlexusDx and MEDVi keep that door open inside one platform; Hers does not on its compounded path.

Why genetics matter before you choose

GLP-1 response varies meaningfully across patients. Variants in GLP1R (the GLP-1 receptor itself), GIPR (the GIP receptor — rs1800437 is the headline variant), FTO (appetite regulation), MC4R (satiety signaling), and TCF7L2 (insulin response) are associated with measurably different response patterns to semaglutide and tirzepatide. The Precision Peptide Genetic Test maps 48 genes and 57 variants across 14 health pathways — including 34 weight-management insights and the GIPR rs1800437 variant linked to differential GLP-1 response — so the prescribing clinician can weigh whether a faster-than-typical titration, a slower one, or a tirzepatide-first approach is more likely to fit your biology before week one. Neither MEDVi nor Hers performs this step on their standard intake — both start from a population-average titration schedule and adjust based on subjective tolerability over the first 8–12 weeks. PlexusDx anchors that same conversation to a measurable genetic baseline, available standalone for $298 or as a $99 add-on after your first month on any protocol.

Cancellation, refund policy, and financial downside

The cancellation terms differ in ways that matter if you stop early. MEDVi requires 72 hours notice before your next billing date through the patient portal or hello@medvi.org; there is no contract penalty, but ordinary cancellation does not qualify for a refund under MEDVi's current published policy — refunds apply only if you are medically disqualified. Hers requires 2 days advance cancellation through the app or website for both the Weight Loss Membership and the Medication Plan separately. Initial Medication Plan orders are refundable only if canceled within 48 hours of payment. No refunds for partially used Membership or Medication Plan periods, and no refund for medication after it has shipped. PlexusDx bills per protocol cycle with no membership and no multi-month prepay requirement; cash-pay, all 50 states (5 require a scheduled live consult rather than async). For a patient who is uncertain whether GLP-1 will fit their biology, the lowest financial-downside entry points are PlexusDx's Microdose GLP-1 Protocol at $129/mo flat and MEDVi's $179 first month; the highest commitment is any prepaid multi-month plan.

Which one fits — a five-question frame

Question 1: Does your insurance reliably cover Wegovy, Ozempic, or Zepbound at a low copay? If yes, Hers's branded path plus your benefit is likely cheapest. Question 2: Are you cash-pay with no GLP-1 coverage and price is the dominant factor? Compare MEDVi's $3,468/year all-inclusive to PlexusDx Microdose GLP-1 Protocol at $1,548/year or Semaglutide Injection at $2,148–$2,748/year. Question 3: Do you want compounded tirzepatide as a backup if semaglutide stalls? MEDVi and PlexusDx keep that option open in one platform; Hers does not on its compounded path. Question 4: Do you want the polished iOS/Android app experience with a Care Team? Hers leads on app and Care Team. Question 5: Do you want a genetic baseline informing dose and titration before the first injection? PlexusDx is the only option in this comparison that includes the Precision Peptide Genetic Test as part of the protocol pathway.

Frequently asked questions

Is MEDVi cheaper than Hers?

It depends on which Hers path you compare against. MEDVi's compounded all-inclusive plan is $179 first month then $299/mo ongoing, month-to-month. Hers now bundles a required Weight Loss Membership with separate medication pricing — Wegovy® pill from $149/mo, Wegovy® pen and Ozempic® from $199/mo, generic liraglutide from $299/mo — so the headline price plus membership often lands at or above MEDVi annually. PlexusDx Microdose GLP-1 Protocol at $129/mo flat is below both.

Is the semaglutide from MEDVi or PlexusDx the same as Wegovy?

No. Both MEDVi and PlexusDx prescribe compounded semaglutide, prepared by a licensed compounding pharmacy. Compounded semaglutide is not an FDA-approved finished drug product and has not undergone separate FDA clinical trials. Wegovy is the FDA-approved branded semaglutide manufactured by Novo Nordisk. The active ingredient is semaglutide in both cases.

Is MEDVi FDA-approved?

The FDA does not approve telehealth platforms; it approves finished drug products. MEDVi's compounded GLP-1 medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality as finished products. The same regulatory framing applies to PlexusDx compounded protocols. Only branded products like Wegovy, Ozempic, Zepbound, and Mounjaro are FDA-approved.

Does Hers offer compounded tirzepatide?

No. Hers does not currently offer compounded tirzepatide on its weight-loss platform. Brand-name Mounjaro® and Zepbound® are listed at branded pricing tiers. MEDVi offers compounded tirzepatide injectable from $349/mo and tablets from $279/mo. PlexusDx offers Tirzepatide Injection at $249/mo and Tirzepatide Oral at $279/mo.

Can I use HSA or FSA to pay for MEDVi, Hers, or PlexusDx?

HSA and FSA eligibility for GLP-1 weight-loss treatment depends on your specific plan administrator's rules, but it generally qualifies as a medical expense under most plans. MEDVi and Hers both accept HSA/FSA payments. PlexusDx accepts HSA/FSA where applicable; check with your plan administrator first.

How does PlexusDx use genetics to personalize GLP-1 dosing?

The Precision Peptide Genetic Test maps 48 genes and 57 variants across 14 health pathways, including 34 weight-management insights. The headline variant is GIPR rs1800437, associated with differential GLP-1 response. Available standalone for $298 or as a $99 add-on after your first month on any PlexusDx protocol. Neither MEDVi nor Hers performs genetic stratification on standard intake.

What if my GLP-1 medication arrives warm?

Do not use it. Injectable GLP-1 medications require cold-chain shipping. Document the packaging condition with photos, contact your provider immediately, and request a replacement. MEDVi, Hers, and PlexusDx all replace compromised shipments at no additional charge under standard policy.

MEDVi vs Hers vs PlexusDx (2026): Cost, Coverage & Genetics-Informed GLP-1 | PlexusDx